Navigation Links
Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
Date:6/23/2008

NEW YORK, June 23 /PRNewswire/ -- Danube Pharmaceuticals, Inc., a privately held biopharmaceutical company specializing in the commercial research and development of innovative drugs for ophthalmology, is pleased to announce the appointment of Dr. Brian Levy, OD, MSc as its Chief Operating Officer.

"Dr. Levy's depth and breathe of experience in clinical operations, drug and device development and medical affairs make him an excellent addition to Danube's senior management team. I look forward to his working with us in successfully developing our drug candidates and expanding our pipeline," said Barrett Katz, MD, MBA, Chief Executive Officer of Danube.

Prior to joining Danube, since 2004, Dr. Levy served as Corporate Vice President and Chief Medical Officer of Bausch & Lomb worldwide. He was responsible for clinical development and research, global product safety and medical affairs. In this role Dr. Levy drove the development and subsequent approval of multiple ophthalmic pharmaceutical products and ophthalmic devices globally, including the only approved intra-ocular sustained release steroid drug delivery system. Dr. Levy joined Bausch & Lomb in 1994 as Director, Medical Clinical Affairs. Prior to joining Bausch & Lomb, from 1989 to 1994, Dr. Levy served as Associate Professor in the Department of Ophthalmology at California Pacific Medical Center in San Francisco. Before that he studied epidemiology and biostatistics in vision research through the National Institutes of Health and then proceeded into private clinical practice for 10 years. During this period Dr. Levy was a clinical investigator for numerous products in development and an advisor and consultant to the ophthalmic industry.

Dr. Levy currently holds an appointment as Clinical Professor in the Department of Ophthalmology at the University of Rochester's School of Medicine. He received a Doctor of Optometry degree from the University of California at Berkeley and did his post-graduate work in comparative anatomy and physiology of the eye at the University of Waterloo in Canada, where he received a Master of Science degree. Dr. Levy has published widely in peer-reviewed journals and has presented nationally and internationally at scientific and educational symposia of Ophthalmology.

About Danube Pharmaceuticals, Inc.

Danube is a biopharmaceutical company dedicated to the research and development of treatments for diseases of the eye. Danube's lead compound DNB-001, is a small molecule for the treatment of glaucoma available in both oral and topical formulation. In preclinical studies DNB-001 has been shown through novel mechanisms of action to both lower intraocular pressure (IOP) and to provide direct neuroprotective benefits to the optic nerve and its retinal ganglion cells, providing a dual approach to glaucoma therapy not provided by any currently marketed product. DNB-001 has been tested in a Phase I clinical trial in Europe and is currently being studied in a Phase II clinical trial in Europe. For more information on Danube please visit http://www.danubepharma.com.

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statements. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, and product pricing and third party reimbursement. We undertake no obligation to update any forward-looking statement contained in this press release, except as required by law.


'/>"/>
SOURCE Danube Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Brian J.G. Pereira, M.D. Joins Biodels Board of Directors
2. MiMedx Announces Brian J. Splan as President
3. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
4. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
5. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
6. Miaxis Biometrics Named as Red Herring 100 Asia Award Winner for 2007
7. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
8. Hyaluron Contract Manufacturing Named a 2007 Economic Impact Award Finalist
9. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
10. Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year
11. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... PBI-Gordon Corporation is pleased to ... , Doug began his career at PBI-Gordon in February 1988, after finishing his ... variety of roles, ranging from customer service to national product manager, to helping develop, ...
(Date:5/3/2016)... ... 03, 2016 , ... Morf Media Inc ., developer ... on mobile devices, today released a new interactive Food and Drug Administration ... course is essential for owners or operators of places of business that are ...
(Date:5/3/2016)... ... 03, 2016 , ... Flagship Biosciences, the leader in ... Board of Directors. Dr. Gillett recently retired from Charles River Laboratories (CRL), where, ... Scientific Officer. A board-certified veterinary pathologist, Dr. Gillett joined Charles River in 1999 ...
(Date:5/3/2016)... 2016 - And Other Rising ... of Those Competitor Biologics  - Biosimilar Drug ... Prospects ,  Who are the most important ... are their sales potentials? Discover, in our updated survey, ... opportunities and revenue forecasting. Visiongain,s ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
Breaking Biology News(10 mins):